2658-6533Научные результаты биомедицинских исследований2658-653310.18413/2658-6533-2020-6-1-0-71964Фармакология, клиническая фармакология<strong>Комплексная оценка коррекции очищенной микронизированной флавоноидной фракцией нарушений при ADMA-подобной преэклампсии в эксперименте</strong><br /> &nbsp;<strong>Comprehensive assessment of using micronised purified flavonoid fraction in the correction of disorders associated with ADMA-like preeclampsia in experiment</strong><br /> &nbsp;АнцифероваОксана ЕвгеньевнаAntsiferovaOksana E.AnciferovaO@ya.ruГуреевВладимир ВладимировичGureevVladimir V.produmen@yandex.ruГурееваАнастасия ВладимировнаGureevaAnastasia V.nastasyi.207@gmail.comАвдееваЕлена ВладимировнаAvdeevaElena V.avdeyeva_ev@mail.ruМихайловаЮлия АлександровнаMikhailovaYulia A.myil75@mail.ruКузьминДмитрий БорисовичKuzminDmitriy B.dmitriy.kuzmin.79@bk.ru20206100

Актуальность: Около 10% беременностей в мире сопровождается гипертензивными расстройствами, при этом от 2 до 8% приходится на преэклампсию. Одним из компонентов патогенеза преэклампсии является плацентарная ишемия. Выделяющиеся при ней гуморальные факторы обладают провоспалительным эффектом и могут способствовать развитию эндотелиальной дисфункции. Одним из возможных вариантов сниженя эффектов этих цитокинов может явиться использование препаратов содержащих природные флавоноиды,&nbsp; одним из положительных моментов которых является снижение веноспецифического воспаления. Цель исследования: Исследовать эффективность использования очищенной микронизированной флавоноидной фракции при коррекции функциональных нарушений, возникающих при преэклампсии в эксперименте. Материалы и методы: Эксперимент выполнен на 100 белых крысах-самках линии Wistar массой 250-300 г. ADMA-подобный агент &ndash; (L-NAME) вводили внутрибрюшинно в дозе 25 мг/кг/сут в c 14 по 20 сут. беременности. Очищенную микронизированную флавоноидную фракцию (диосмин+флавоноиды в пересчете на гесперидин) в дозировках 86 мг/кг и 260 мг/кг вводили перорально однократно в сутки с 14 по 20 сутки беременности. На 21 сутки беременности проводили функциональные пробы и лабораторные исследования. Результаты: Введение лабораторным животным очищенной микронизированной флавоноидной фракции приводит к выраженной коррекции патологических изменений при экспериментальной ADMA-подобной преэклампсии с наибольшим эффектом в большей дозе используемого препарата. Отмечалось достоверное снижение систолического и диастолического давления соответственно, улучшение микроциркуляции в плаценте, восстановление NO-синтезирующей функции эндотелия, уменьшении протеинурии. Заключение: Результаты проведенного исследования свидетельствуют о перспективности применения очищенной микронизированной флавоноидной фракции для коррекции морфофункциональных изменений при преэклампсии и обосновывают целесообразность дальнейших исследований в этом направлении.

Background: About 10% of pregnancies in the world are accompanied by&nbsp;hypertensive disorders, while from 2 to 8% are preeclampsia. One of the components of the pathogenesis of preeclampsia is placental ischemia. The humoral factors released during preeclampsia have a pro-inflammatory effect and can contribute to the development of endothelial dysfunction. One of the possible options for reducing the effects of these cytokines may be the use of drugs containing natural flavonoids, one of the positive aspects of which is the reduction of venospecific inflammation. The aim of the study: To study the effectiveness of using purified micronized flavonoid fraction (diosmin+flavonoids expressed as hesperidin) in the correction of functional disorders that occur during preeclampsia in the experiment. Materials and methods: The experiment was performed on 100 white female rats of the Wistar line weighing 250-300 g. ADMA-like agent (L-NAME) was introduced intraperitoneally at a dose of 25 mg/kg/day from 14 to 20 days of gestation. The purified micronized flavonoid fraction (diosmin + flavonoids expressed as hesperidin) in dosages of 86 mg/kg and 260 mg/kg was administered orally once a day from 14 to 20 days of pregnancy. On the 21st day of pregnancy, functional tests and laboratory tests were performed. Results: The administration of purified micronized flavonoid fraction to laboratory animals leads to a pronounced correction of pathological changes in experimental ADMA-like preeclampsia with the greatest effect in a higher dose of the drug used. A significant decrease in systolic and diastolic pressure was noted, respectively, improved microcirculation in the placenta, restoration of the NO-synthesizing function of the endothelium, and a decrease in proteinuria. Conclusion: The results of the study indicate the promise of using a purified micronized flavonoid fraction for the correction of functional changes in preeclampsia and substantiate the feasibility of further research in this direction.

очищенная микронизированная флавоноидная фракцияпреэклампсияэндотелиальная дисфункциякрысыпротеинуриямикроциркуляцияpurified micronized flavonoid fractionpreeclampsiaendothelial dysfunctionratsproteinuriamicrocirculationСписок литературыGhulmiyyah L., Sibai B. Maternal mortality from preeclampsia/eclampsia // Semin Perinatol. 2012. Vol. 36(1). P. 56-9. DOI: https://doi.org/10.1053/j.semperi.2011.09.011Complex Analysis of Total and Fetal DNA and Cytokines in Blood Plasma of Pregnant Women with Preeclampsia / A.M. Krasnyi [et al.] // Bull Exp Biol Med. 2018. Vol. 164. P. 721-725. DOI: https://doi.org/10.1007/s10517-018-4066-1Das U.N. Cytokines, angiogenic, and antiangiogenic factors and bioactive lipids in preeclampsia. Nutrition. 2015. Vol. 31(9). P. 1083-95. DOI: https://doi.org/10.1016/j.nut.2015.03.013Hypoxia-independent up regulation of placental hypoxia inducible factor 1 alpha gene expression contributes to the pathogenesis of preeclampsia / T. Iriyama [et al.] // Hypertension 2015. Vol. 65(6). P. 1307-1315. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.115.05314Воронков А.В., Гамзелева О.Ю. Обзор современных флеботропных препаратов на основе флавоноидов как перспективных эндотелиопротекторов при лечении хронических заболеваний вен // Стационарозамещающие технологии: Амбулаторная хирургия. 2019. N 1-2. C. 27-33. DOI: https://doi.org/10.21518/1995-1477-2019-1-2-27-33Evaluation of Pharmacological Correction of L-NAME-induced Endothelial Dysfunction, Platelet Aggregation and Venous Tone With Diosmin &quot;Detralex 1000 mg&quot; / Y. Lukyanova [et al.] // Research Results in Pharmacology 2018. Vol. 4(4). P. 1-7. DOI: https://doi.org/10.3897/rrpharmacology.4.31748Mansilha A., Sousa J. Pathophysiological Mechanisms of Chronic Venous Disease and Implications for Venoactive Drug Therapy // Int J Mol Sci. 2018. Vol. 19(6). pii: E1669. DOI: https://doi.org/10.3390/ijms19061669A review on pharmacological and analytical aspects of diosmetin: a concise report / K. Patel [et al.] // Chin J Integr Med. 2013. Vol. 19(10). P. 792-800. DOI: 10.1007/s11655-013-1595-3The Potential Protective Effects of Diosmin on Streptozotocin-Induced Diabetic Cardiomyopathy in Rats / T.M. Ali [et al.] // Am J Med Sci. 2020. Vol. 359(1). P. 32-41. DOI: 10.1016/j.amjms.2019.10.005HPLC characterization, acute and sub-acute toxicity evaluation of bark extract of Rhizophora mucronata in Swiss Albino mice / J. Chitra [et al.] // Heliyon. 2019. Vol. 6(1). P. e03108. DOI: 10.1016/j.heliyon.2019.e03108Polyphenol characterisation of Phoenix dactylifera L. (date) seeds using HPLC-mass spectrometry and its bioaccessibility using simulated in-vitro digestion/Caco-2 culture model / S. Hilary [et al.] // Food Chem. 2020. Vol. 311. P. 125969. DOI: 10.1016/j.foodchem.2019.125969Klimek-Szczykutowicz M., Szopa A., Ekiert H. Citrus limon (Lemon) Phenomenon-A Review of the Chemistry, Pharmacological Properties, Applications in the Modern Pharmaceutical, Food, and Cosmetics Industries, and Biotechnological Studies // Plants (Basel). 2020. Vol. 9(1). P. E119. DOI: 10.3390/plants9010119Ultrasound-Assisted Extraction Optimization of Phenolic Compounds from Citrus latifolia Waste for Chitosan Bioactive Nanoparticles Development / N. Medina-Torres [et al.] // Molecules. 2019. Vol. 24(19). P. E3541. DOI: 10.3390/molecules24193541Curr&ograve; D. The role of gut microbiota in the modulation of drug action: a focus on some clinically significant issues // Expert Rev Clin Pharmacol. 2018. Vol. 11(2). P. 171-183. DOI: 10.1080/17512433.2018.1414598Profiling and comparison of the metabolites of diosmetin and diosmin in rat urine, plasma and feces using UHPLC-LTQ-Orbitrap MSn / X. Chen [et al.] // J Chromatogr B Analyt Technol Biomed Life Sci. 2019. Vol. 1124. P. 58-71. DOI: 10.1016/j.jchromb.2019.05.030Inhibition of autophagy via activation of PI3K/Akt/mTOR pathway contributes to the protection of hesperidin against myocardial ischemia/reperfusion injury / X. Li [et al.] // International Journal of Molecular Medicine. 2018. Vol. 42(4). P. 1917-1924. DOI: https://doi.org/10.3892/ijmm.2018.3794Protective effects of hesperidin and diosmin against acrylamide-induced liver, kidney, and brain oxidative damage in rats / A.E. Elhelaly [et al.] // Environ Sci Pollut Res Int. 2019. Vol. 26(34). P. 35151-35162. DOI: 10.1007/s11356-019-06660-3Sl&iacute;va J. Diosmin - still an important modality in the treatment of venous insufficiency // Vnitr Lek. 2019. Vol. 65(7-8). P. 524-526.Lichota A., Gwozdzinski L., Gwozdzinski K. Therapeutic potential of natural compounds in inflammation and chronic venous insufficiency // Eur J Med Chem. 2019. Vol. 176. P. 68-91. DOI: 10.1016/j.ejmech.2019.04.075Akhmetzianov R.V., Bredikhin R.A. Clinical efficacy of Detralex in treatment of women with pelvic varicose veins // Angiol Sosud Khir. 2018. Vol. 24(2). P. 93-99.Rodnyansky D.V., Fokin A.A. Diosmin-containing phlebotropic drugs in varicose eczema // Angiol Sosud Khir. 2019. Vol. 25(3). P. 88-92. DOI: 10.33529/ANGI02019303Influence of Diosmin Treatment on the Level of Oxidative Stress Markers in Patients with Chronic Venous Insufficiency / V. Feldo [et al.] // Oxid Med Cell Longev. 2018. Vol. 2018. Article ID 2561705. DOI: 10.1155/2018/2561705Zagriadskiĭ E.A., Bogomazov A.M., Golovko E.B. Conservative Treatment of Hemorrhoids: Results of an Observational Multicenter Study // Adv Ther. 2018. Vol. 35(11). P. 1979-1992. DOI: 10.1007/s12325-018-0794-xFlavonoid mixture (diosmin, troxerutin, rutin, hesperidin, quercetin) in the treatment of I-III degree hemorroidal disease: a double-blind multicenter prospective comparative study / I. Corsale [et al.] // Int J Colorectal Dis. 2018. Vol. 33(11). P. 1595-1600. DOI: 10.1007/s00384-018-3102-yBashankaev B.N., Wexner S.D., Arkharov A.V. Common sense of diosmin administration in combined treatment of hemorrhoids // Khirurgiia (Mosk). 2018. Vol. 8. Vyp. 2. P. 83-89. DOI: 10.17116/hirurgia201808283Effectiveness and safety of a mixture of diosmin, coumarin and arbutin (Linfadren&reg;) in addition to conventional treatment in the management of patients with post-trauma/surgery persistent hand edema: a randomized controlled trial / A. Cacchio [et al.] // Clin Rehabil. 2019. Vol. 33(5). P. 904-912. DOI: 10.1177/0269215519829797Effectiveness and safety of a product containing diosmin, coumarin, and arbutin (Linfadren&reg;) in addition to complex decongestive therapy on management of breast cancer-related lymphedema / A. Cacchio [et al.] // Support Care Cancer. 2019. Vol. 27(4). P. 1471-1480. DOI: 10.1007/s00520-018-4514-5The effects of diosmin and hesperidin on capillary blood flow of upper limbs in patients with secondary Raynaud&#39;s syndrome / A.M. Zudin [et al.] // Khirurgiia (Mosk). 2017. Vol. 5. P. 60-66. DOI: 10.17116/hirurgia2017560-66Effect of Diosmin Administration in Patients with Chronic Venous Disorders on Selected Factors Affecting Angiogenesis / M. Feldo [et al.] // Molecules. 2019. Vol. 24(18). P. E3316. DOI: 10.3390/molecules24183316Wojnar W., Kaczmarczyk-Sedlak I., Zych M. Diosmin ameliorates the effects of oxidative stress in lenses of streptozotocin-induced type 1 diabetic rats. Pharmacol Rep. 2017. Vol. 69(5). P. 995-1000. DOI: 10.1016/j.pharep.2017.04.005Diosmin Nanocrystal-Loaded Wafers for Treatment of Diabetic Ulcer: In Vitro and In Vivo Evaluation / N.M. Atia [et al.] // J Pharm Sci. 2019. Vol. 108(5). P. 1857-1871. DOI: 10.1016/j.xphs.2018.12.019Protective effect of diosmin against diabetic neuropathy in experimental rats / D. Jain [et al.] // J Integr Med. 2014. Vol. 12(1). P. 35-41. DOI: 10.1016/S2095-4964(14)60001-7The Benefits of the Citrus Flavonoid Diosmin on Human Retinal Pigment Epithelial Cells under High-Glucose Conditions / W.Y. Liu [et al.] // Molecules. 2017. Vol. 22(12). P. E2251. DOI: 10.3390/molecules22122251Diosmin Modulates the NF-kB Signal Transduction Pathways and Downregulation of Various Oxidative Stress Markers in Alloxan-Induced Diabetic Nephropathy / S. Ahmed [et al.] // Inflammation. 2016. Vol. 39(5). P. 1783-97. DOI: 10.1007/s10753-016-0413-4Diosmin, a Citrus Nutrient, Activates Imidazoline Receptors to Alleviate Blood Glucose and Lipids in Type 1-Like Diabetic Rats / C.C. Hsu [et al.] // Nutrients. 2017. Vol. 9(7). P. E684. DOI: 10.3390/nu9070684Antihyperglycaemic action of diosmin, a citrus flavonoid, is induced through endogenous &beta;-endorphin in type I-like diabetic rats / C.C. Hsu [et al.] // Clin Exp Pharmacol Physiol. 2017. Vol. 44(5). P. 549-555. DOI: 10.1111/1440-1681.12739El-Fawal R., El Fayoumi H.M., Mahmoud M.F. Effects of diosmin and crocin on metabolic syndrome-associated cardio-vascular complications in rats // Naunyn Schmiedebergs Arch Pharmacol. 2019. Vol. 392(12). P. 1523-1536. DOI: 10.1007/s00210-019-01700-8El-Fawal R., El Fayoumi H.M., Mahmoud M.F. Diosmin and crocin alleviate nephropathy in metabolic syndrome rat model: Effect on oxidative stress and low grade inflammation // Biomed Pharmacother. 2018. Vol. 102. P. 930-937. DOI: 10.1016/j.biopha.2018.03.162In vitro-in vivo evaluation of chitosan-PLGA nanoparticles for potentiated gastric retention and anti-ulcer activity of diosmin / W.E. Abd ElHady [et al.] // Int J Nanomedicine. 2019. Vol. 14. P. 7191-7213. DOI: 10.2147/IJN.S213836Shalkami A.S., Hassan M., Bakr A.G. Anti-inflammatory, antioxidant and anti-apoptotic activity of diosmin in acetic acid-induced ulcerative colitis // Hum Exp Toxicol. 2018. Vol. 7(1). P. 78-86. DOI: 10.1177/0960327117694075Diosmin for the prevention of ovarian hyperstimulation syndrome [Electronic] / T. Li [et al.] // Int J Gynaecol Obstet. 2020. URL: https://obgyn.onlinelibrary.wiley.com/doi/pdf/10.1002/ijgo.13100 (дата обращения: 20.01.2020) DOI: 10.1002/ijgo.13100Effect of Bioactive Phytochemicals from Phlomis viscosa Poiret on Wound Healing / L. Yarmolinsky [et al.] // Plants (Basel). 2019. Vol. 8(12). P. E609. DOI: 10.3390/plants8120609Shabani S., Mirshekar M.A. Diosmin is neuroprotective in a rat model of scopolamine-induced cognitive impairment // Biomed Pharmacother. 2018. Vol. 108. P. 1376-1383. DOI: 10.1016/j.biopha.2018.09.127Diosmin improved cognitive deficit and amplified brain electrical activity in the rat model of traumatic brain injury / M.A. Mirshekar [et al.] // Biomed Pharmacother. 2017. Vol. 93. P. 1220-1229. DOI: 10.1016/j.biopha.2017.07.014A Randomized Controlled Trial Evaluating the Effects of Diosmin in the Treatment of Radicular Pain / Y. Wang [et al.] // Biomed Res Int. 2017. Vol. 2017. Article ID 6875968. DOI: 10.1155/2017/6875968Central and peripheral anti-hyperalgesic effects of&nbsp;diosmin in a neuropathic pain model in rats / A.I. Carballo-Villalobos [et al.] // Biomed Pharmacother. 2018. Vol. 97. P. 310-320. DOI: 10.1016/j.biopha.2017.10.077Targeting Keap-1/Nrf-2 pathway and cytoglobin as a potential protective mechanism of diosmin and pentoxifylline against cholestatic liver cirrhosis / F.E.M. Ali [et al.] // Life Sci. 2018. Vol. 207. P. 50-60. DOI: 10.1016/j.lfs.2018.05.048Gelle P., Crepin G., Delahousse G. Varices in pregnancy. Use of Daflon // Lille Med. 1972. Vol. 17(7). P. 1466-8.The interest and prospects of Daflon treatment in obstetrical and gynaecological practice / P. Muller [et al.] // Rev Fr Gynecol Obstet. 1973. Vol. 68(5). P. 345-9.Buckshee K., Takkar D., Aggarwal N. Micronized flavonoid therapy in internal hemorrhoids of pregnancy // Int J Gynaecol Obstet. 1997. Vol. 57(2). P. 145-51.Using phlebodia in pregnant women during preterm delivery / N. Milchev [et al.] // Akush Ginekol (Sofiia). 2008. Vol. 47(5). P. 7-9.Lakhno I.V. Pathogenetic percularities of fetal distress in pregnant women with preeclampsia // Georgian Med News. 2013. Vol. 223. P. 11-6.First epidemiological data for venotonics in pregnancy from the EFEMERIS database / I. Lacroix [et al.] // Phlebology. 2016. Vol. 31(5). P. 344-8. DOI: 10.1177/0268355515589679Polish Gynecological Society. Recommendations of the Polish Gynecological Society expert panel on the use of Detramax in pregnancy // Ginekol Pol. 2015. Vol. 86(12). P. 962-5.Комплексная оценка коррекции триметазидином морфофункциональных нарушений при ADMA-подобной преэклампсии / О.Е. Анциферова [и др.] // Вестник Смоленской государственной медицинской академии 2019. Т. 18, N 1. С. 103-108.Gureev V. New approaches of morfofunktional pharmacological correction of violations of cardiovascular system in experimental Preeclampsia // Research Results in Pharmacology. 2016. Vol. 2(3). P. 11-27. DOI: https://doi.org/10.18413/2500-235X-2016-2-3-11-27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protective role of hesperidin against &gamma;-radiation-induced oxidative stress and apoptosis in rat testis / N.Z. Shaban [et al.] // Journal of Biological Research-Thessaloniki. 2017. Vol. 24. P. 5. DOI: https://doi.org/10.1186/s40709-017-0059-xMolecular mechanisms of the effects of the ethanolic extract of Muntingia calabura Linn. fruit on lipopolysaccharide-induced pro-inflammatory mediators in macrophages / J.T. Lin [et al.] // Food Funct. 2017. Vol. 8(3). P. 1245-1253. DOI: 10.1039/c6fo01735eBerkoz M. Diosmin suppresses the proinflammatory mediators in lipopolysaccharide-induced RAW264.7 macrophages via NF-&kappa;B and MAPKs signal pathways // Gen Physiol Biophys. 2019. Vol. 38(4). P. 315-324. DOI: 10.4149/gpb_2019010A comparative study of the protective effect of different phlebotonic agents on endothelial cells in hypoxia / C. Michiels [et al.] // Phlebologie. 1991. Vol. 44(3). P. 779-86.Moderate Effect of Flavonoids on Vascular and Renal Function in Spontaneously Hypertensive Rats / M.D. Paredes [et al.] // Nutrients. 2018. Vol. 10(8). P. E1107. DOI: 10.3390/nu10081107Beneficial Effects of Different Flavonoids on Vascular and Renal Function in L-NAME Hypertensive Rats / M.D. Paredes [et al.] //Nutrients. 2018. Vol. 10(4). P. E484. DOI: 10.3390/nu10040484Ma Y., Tan F., Yu S. Diosmin inhibits apoptosis of vascular endothelial cells in rats with traumatic deep vein thrombosis through JAK-STAT signaling pathway [Electronic] // Panminerva Med. 2019. URL: https://www.minervamedica.it/en/journals/panminerva-medica/article.php?cod=R41Y9999N00A19092403 (дата обращения: 20.01.2020) DOI: 10.23736/S0031-0808.19.03718-2Endotheliotropic effects of venotonic drugs in treatment of patients with varicose veins / R.E. Kalinin [et al.] // Angiol Sosud Khir. 2018. Vol. 24(4). P. 72-74.Gurfinkel&#39; I.I., Sasonko M.L., Talov N.A. Correction of blood microcirculation parameters and endothelial function in chronic venous insufficiency of lower limbs // Angiol Sosud Khir. 2017. Vol. 23(2). P. 89-95.Diosmin protects against cerebral ischemia/reperfusion injury through activating JAK2/STAT3 signal pathway in mice / X. Liu [et al.] // Neuroscience. 2014. Vol. 268. P. 318-27. DOI: 10.1016/j.neuroscience.2014.03.032The effect of diosmin on pancreatic injury induced by hepatic ischemia reperfusion in rats / S.S. Kilicoglu [et al.] // Bratisl Lek Listy. 2013. Vol. 114(3). P. 119-24.Effects of Citrus Flavonoids Against Microvascular Damage Induced by Hypoperfusion and Reperfusion in Rat Pial Circulation / T. Mastantuono [et al.] // Microcirculation. 2015. Vol. 22(5). P. 378-90. DOI: 10.1111/micc.12207